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Abstract: Evolving atrophic macular degeneration represents at least
80% of all macular degenerations and is currently without a standar-
dized care. Autologous fat transplantation efficacy was demonstrated by
several studies, as these cells are able to produce growth factors. The
aim of the work was to demonstrate possible therapeutic effect of the
joined suprachoroidal graft of adipocytes, adipose-derived stem cells
(ADSCs) in stromal vascular fractions (SVFs) of adipose tissue, and
platelet-rich plasma (PRP).
Twelve eyes in 12 dry age-related macular degeneration (AMD)
patients, aged 71.25 (SD 6.8) between 62 and 80 years, were analyzed.
A complete ocular evaluation was performed using best corrected visual
acuity (BCVA), retinographic analysis, spectral-domain optical coher-
ence tomography, microperimetry, computerized visual field, and stan-
dard electroretinogram (ERG). Each eye received a cell in graft between
choroid and sclera of mature fat cells and ADSCs in SVF enriched with
PRP by means of the variant second Limoli (Limoli retinal restoration
technique [LRRT]). In order to test if the differences pre- and post-
treatment were significant, the Wilcoxon signed-rank test has been
performed.
Adverse effects were not reported in the patients. After surgery
with LRRT, the most significant increase in the ERG values was
recorded by scotopic rod-ERG (answer coming from the rods), from
41.26 to 60.83mV with an average increase of 47.44% highly sig-
nificant (P< 0.05). Moderately significant was the one recorded by
scotopic maximal ERG (answer coming from the rods and cones),
from 112.22 to 129.68mV with an average increase of 15.56%Vingolo, Marco Ul MD, PhD,
Celeste Limoli, MD, PhD
in the short term. The ERG could, therefore, be used to monitor the
effect of cell-mediated regenerative therapies.
(Medicine 93(29):e355)
Abbreviations: mV = microvolts, ADSCs = adipose derived stem-
cells, AFT = Autologous fat transplantation, AMD = age-related
macular degeneration, BCVA = best corrected visual acuity for far
distance, bFGF = basic fibroblast growth factor, Close up = visual
acuity for near vision, EGF = epidermal growth factor, ERG =
electroretinogram, ETDRS = early treatment diabetic retinopathy
study, G0 phase = cell quiescence abandonment, G1 phase = cell
entry in the phase growth, GM-CSF = granulocyte-macrophage
colony-stimulating factor, IGF-1 = insulin-like growth factor-1, IL
= interleukin, logMAR = logarithm of the minimum angle of
resolution, LRRT = Limoli retinal restoration technique, M-CSF =
macrophage colony-stimulating factor, NS = not statistically
significant, PDAF = platelet-derived angiogenesis factor, PDGF =
platelet-derived grow factor, PEDF = pigment-epithelium-derived
factor, PlGF = placental growth factor, PRP = platelet rich plasma,
Pts = points, RPEs = retinal pigment epithelial cells, SD = standard
deviation, SVF = stromal vascular fractions, T0 = time before of
autograft cells, T30 = time after 30 days of autograft cells, TGF-b
= transforming growth factor-b, TSP = thrombospondin, VEGF =
vascular endothelial growth factor.
INTRODUCTION
E volving atrophic macular degeneration represents at least80% of all macular degenerations and is currently without a
standardized care. However, since the 1990s, a series of studies
using growth factors to block or slow retinal atrophy has
begun.1–9 The eredodistrophic guinea pigs allow to note the
photoreceptor survival promotion, counting the nuclear layer
thickness after intravitreal injection of growth factor.10,11
Application of therapy for regenerative purpose in humans
is hampered by the rapid half-life of these factors that would
require intraocular injections at least every 2 months, with the
potential implications that it entail. In fact, some serious side
effects have been noted including macular hemorrhages,
vitreoretinal interface alterations, intravitreal hemorrhages,
retinal detachment, cataract, proliferative vitreoretinopathy,
and endophthalmitis.1,12,13
One possible source of autologous growth factors is
represented by adipose tissue.14–17
Autologous fat transplantation efficacy was demonstrated
by Filatov’s18 work and Pelaez’s19 work first and from those of
Meduri et al20 and Limoli21,22 later.
The authors describe functional stabilization in 60% of
cases, functional improvement in 15% to 20% of cases, andcases. The clinical results, even though
, and after 6 to 18 months, according to
and the type of patient being treated,
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2.
4.degenerative disease and apoptotic processes linked to it resume
their destructive action against the retina.
Other useful autologous sources are derivable from platelet-
rich plasma (PRP) and adipose-derived stem cells (ADSCs)
included in stromal vascular fractions (SVF) of adipose tissue.23–27
These elements, surgically grafted into suprachoroidal
space, might delay retinal cell apoptosis through an almost
pharmacological modulation of their secretions.23–27
Trophic effects of growth factors on retina are shown by the
histological examination in guinea pig, considering the nuclear
layer thickness of photoreceptors compared with untreated eye.
Therefore, clinical study is not possible on retina in
humans. Moreover, human pathological variables are much
more complex than those encountered in genetically modified
animal models and treated under standard conditions.5,28
Moreover, similarly to the method of assessment used in
animal models, we can use the electrophysiological testing also
in the study of human retinal degeneration.29,30 In fact, these are
Limoli et alnonicha
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2 |nvasive, objective, and reproducible examinations.
Schematically, for this study, we have divided the electro-retinogram (ERG) into
scotopic rod-ERG that records the electrical response of the1.
rods in the extrafoveal retinal areas;
scotopic maximal rod-cone-ERG that records the electricalplet
only
2.2.
response of the rods and cones of the entire retina;
3. photopic cone-ERG that records the electrical response of
the cones in the foveal retinal area.
It represents a perfect indicator of cell viability, charac-
terizes the quality of the cell electrical responses, and docu-
ments therapeutic effects during medical or surgical
therapies.31–34
The aim of this work was to demonstrate, through the
objectivity of the assessment electrofunctional test, a possible
therapeutic effect of the joined suprachoroidal graft of adipo-
cytes, ADSCs in SVF, and PRP, which, according to the cited
literature, are able to produce growth factors.14–17,23–27 These
factors, pouring in choroidal blood flow, could reach the retinal
cells that are on the opposite side of the choroid, interacting
directly with photoreceptors through their membrane receptors
or indirectly through the interaction with other cells such as
retinal pigment epithelial cells (RPEs), Mu¨ller cells, and
endothelial cells.
PATIENTS AND METHODS
The study protocol was approved by the Ethical Commit-
tee, Low Vision Research of Milan, and in accordance with
Helsinki Declaration, written consent was obtained from all the
patients.35
For this purpose, we have included in the study, 12 eyes of
12 patients affected from dry age-related macular degeneration
(AMD). They were identified and enrolled according to several
racteristics. The inclusion criteria were as follows:
participants of whites classified as well-nourished;
AMD diagnosis with spectral domain optical coherence2.
tomography (SD-OCT), fundus autofluorescence imaging,
and fluorescein angiography in the presence of drusen and
irregularities of RPEs in at least 1 eye;
good storage extrafoveal areas;
measurable visual acuity;
normal intraocular pressure;
www.md-journal.com1.
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informed consent.The exclusion criteria from the study for possible cross-
related interference with the test were as follows:
patients with signs of exudative AMD;
myopia with spherical equivalent >6 diopters;
cataract, chorioretinal disorders, such as macular pucker or3.
neovascular membrane-associated and other ocular dis-
orders (glaucoma, optic neuritis, ocular trauma, high
refractive errors, etc.);
insufficient compliance in individuals affected by medical
problems, such as hypovitaminoses, multiple sclerosis,
epilepsy, Parkinson disease, diabetes, hypertension, vascu-
litis, renal and hepatic diseases, gastrointestinal malabsorp-
tion, hypothyroidism, malignant neoplasias, and other
systemic chronic diseases.
For each patient, the diagnosis was confirmed by confocal
scanning laser ophthalmoscope Nidek F10 (Nidek Inc, Fremont,
CA), SD-OCT Cirrus (Carl Zeiss Meditec AG, Jena, Germany),
and microperimetry Maia 100809 (CenterVue S.p.A., Padova,
Italy) or standard automated perimetry Octopus 900 (Haag-
Streit AG, Koeniz, Switzerland).
Before the graft (T0), for each patient we evaluated best
corrected visual acuity (BCVA) for far and near distance. BCVA
was measured with early treatment diabetic retinopathy study
charts at 4m in logarithm of the minimum angle of resolution
(logMAR) and visual acuity for near vision (close-up) in points
(Pts). Therefore, we recorded the electrical cell activity through
ERG (electromedical system of ocular electrophysiology, Reti-
max; C.S.O. Srl, Scandicci, Italy) according to the standards set
in 2009 by the International Society for Clinical Electrophysi-
ology of Vision.30
Each eye received a cell in graft between choroid and
sclera called for convenience Limoli retinal restoration tech-
nique (LRRT), which is a variant of the intervention of Pelaez,19
who used a transplantation of autologous fat in subscleral space,
obtaining interesting but transient results.21–27
In the LRRT variant, the following changes have been
made with the purpose of increasing the survival of autologous
fat graft,36–38 triggering the proliferation of ADSCs to promote
the growth of choroidal perfusion, and obtaining a more com-
e modulation of the action of the factors secreted by the fat
.39,25–27
The distance between grafted autologous cells and choroid1.
has been reduced by means of deep sclerectomy favoring
the paracrine secretion of the autologous cells into the
choroidal flow.
For the same reason, the area of contact between stalk and
choroid has been expanded.
Suprachoroidal pocket has been built to accommodate the3.
graft and saturated with a mixture of ADSCs and SVF
obtained, according to the technique by Coleman et al36 and
Lawrence et al.374. Adipose pedicle has been infiltrated with PRP gel obtained
b
c
y centrifugation of the blood material, separation of the
omponent, and its platelet degranulation.23,24The details are as follows:
A deep scleral door of about 5 5mm has been opened by a
radial zip in the inferotemporal quadrant to 8mm from the
opyright # 2014 Wolters Kluwer Health, Inc. All rights reserved.
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viewing of the slate color of the choroid.2. Orbital fat is extracted from a gap above the inferior oblique
muscle. The pedicle fat extracted must be sufficient to
ensure the survival of vascular scaffold after its location.3. The flap of autologous fat is laid gently on the bed and
secured with choroidal vicryl 6/0 at the proximal edge of
the door.
The scleral flap is then secured in order to avoid
compression on the fat pedicle or on its nutrient vessels.
The remaining space between autologous fat graft, choroid,5.
and scleral flaps are saturated with 0.5 cc. of SVF,
previously prepared, full of ADSCs by venflon inserted intoing:
2.the scleral pocket.
6. Then, the stroma of the peduncle is infiltrated with 1 cc. of
PRP using 25-gauge cannula.
Therefore, an autograft consisting of fat cells, ADSCs from
SVF, and PRP has been realized.
A month after the LRRT (T30), we evaluated visual acuity
and recorded cellular responses by scotopic, mesopic, and
photopic ERG.
Statistical Analysis
Data were entered into an Access database and then
analyzed with R. After internal consistency checks, statistical
analyses and data visualization were performed before and afterery LRRT. In order to test if the differences pre- and
t-treatment were significant, the Wilcoxon signed-rank test
been performed. The test is well suited when the differences
A
B C
URE 1. Panel (A) Patient affected from dry AMD. Panel (B–C) Micr
after 30 days of autograft cells by variant second Limoli. Scotopic
e-ERG (H–I). AMD¼ age-related macular degeneration. ERG¼ ele
yright # 2014 Wolters Kluwer Health, Inc. All rights reserved.between paired samples are not supposed to be normally
distributed, as in this case. Then, the values of visual acuity,
scotopic-ERG, and photopic-ERG were considered at the var-
ious stages of analysis, and the null hypothesis that there was no
significant treatment effect was rejected if P< 0.05 or P< 0.1.
RESULTS
We have included in the study, 12 eyes (7 right and 5 left
eyes) of 12 patients (6 men and 6 women) with dry AMD,
belonging to patients aged 71.25 years, between 62 and 80 years
(SD 6.8).
The characteristics of the ocular functionality in surgery
patients (Fig. 1) and the average values recorded before (T0)
and after (T30) 30 days of autograft cells by variant second
Limoli are shown in Tables 1 and 2. In any case, we reported
adverse effects, and this highlights the nondangerousness of the
procedure. Mean values recorded before (T0) and after (T30)
surgery of the intraocular pressure were not changed signifi-
Electroretinogram After Autograft in AMDcantloper
rod-
ctroy.
The results after surgery with LRRT indicated the follow-
electrofunctional response from the scotopic rod-ERG1.
(Fig. 2, left panel) has increased from 41.26 to 60.83mV
with an average increase of 47.44%, significant at 5% level
(P< 0.05);
electrofunctional response from the whole retina, scotopic
maximal rod-cone-ERG (Fig. 2, central panel), has
increased from 112.22 to 129.68mV with an average
increase of 15.56%, moderately significant at 10% level
(P< 0.1);
D                                        E
RIGHT -OD RIGHT -OD
RIGHT -OD RIGHT -OD
RIGHT -OD RIGHT -OD
F                                        G
H                                        I
imetric (increased from 7.1 to 12 dB) and ERG changes before
ERG (D–E); scotopic maximal rod-cone-ERG (F–G); photopic
retinogram.
www.md-journal.com | 3
TABLE 1. Mean Values Recorded Before (T0) and After (T30) Surgery With LRRT
BCVA Close-up V Rod-ERG Maximal-ERG Photopic-ERG
Parameter T0 T30 T0 T30 T0 T30 T0 T30 T0 T30
Average 0. 78 0.78 29.5 28.42 41.26 60.83 112.22 129.68 41.61 47.03
Max 1.70 1.70 70 70 74.57 91.75 210.35 179.78 69.90 113.75
Min 0.30 0.30 10 7 8. 28 22.22 67.42 96.35 11.67 19.65
SD () 0.45 0.44 21.7 20.46 20.95 22.98 47.52 30.41 19.3 25.04
BCVA¼ best corrected visual acuity for far distance measured with ETDRS charts at 4m in logMAR, Close-up V¼ visual acuity for near vision in
Pts, ERG¼ electroretinogram amplitude in microvolts, ETDRS¼ early treatment diabetic retinopathy study, logMAR¼ logarithm of the minimum
angle of resolution, LRRT¼Limoli retinal restoration technique, Maximal-ERG¼ scotopic rod-cone-ERG, Photopic-ERG¼ cone-ERG,
Pts¼ points, Rod-ERG¼ scotopic rod-ERG, SD¼ standard deviation.
TABLE 2. Mean Changes Pre- and Post-treatment and Statistical Significance of the Differences With Percentage Change of the
Mean Values
Evaluation Mean Changes Percentage P Value
BCVA 0.004 0.47 0.5539
Close-up V 1.08 3.67 0.7674
Scotopic rod-ERG 19.57 47.44 0.0299

Maximal rod-cone-ERG 17.46 15. 56 0.1047

Photopic cone-ERG 5.41 13 0.5706
The Wilcoxon signed-rank test has been performed. BCVA¼ best corrected visual acuity for far distance in logMAR, Close-up V¼ visual acuity
for near vision in Pts, ERG¼ electroretinogram (amplitude in microvolts), logMAR¼ logarithm of the minimum angle of resolution., Pts¼ points.
Statistical significance of scotopic maximal rod-cone-ERG (P< 0.1).
Higher statistical significance of scotopic rod-ERG (P< 0.05)
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FIGURE 2. Electroretinographic changes. ERG before and after surgery with LRRT. Left Panel. Scotopic rod-ERG has increased from 41.26
to 60.83mV with an average increase of 47.44%, significant at 5% level (P<0.05). Central Panel. Scotopic maximal rod-cone-ERG has
increased from 112.22 to 129.68mV with an average increase of 15.56%, moderately significant at 10% level (P<0.1). Right Panel.
Photopic cone-ERG has increased from 41.61 to 47.03mV with an average increase of 13%, not significant. ERG¼ electroretinogram,
LRRT¼ Limoli retinal restoration technique.
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Copelectrofunctional answer coming from the photopic cone-
RE 3. Visual acuity changes before and after surgery with LRR
AR. Right Panel. Visual acuity for near in Pts. BCVA¼best co
lution, LRRT¼ Limoli retinal restoration technique, Pts¼point3.
ERG (Fig. 2, right panel) has increased from 41.61 to
47.03mV with an average increase of 13%, not significant
(P> 0.05);
0.78 logMAR BCVA remains practically unchanged,4.
therefore, with no significant change (Fig. 3, left panel);
5. Close-up has gone up from 29.5 to 28.42 Pts with variation
of 3.67%, not statistically significant (Fig. 3, right panel).
DISCUSSION
Therefore, the LRRT purpose, that is, the graft joint
rachoroidal adipose pedicle, of ADSCs in SVF, and intra-sup
peduncolar PRP, was as follows:
promote the vascular pedicle fat engraftment with the1.
underlying choroid;
enhance the pedicle fat original vascularization, in order togrowth factors useful from a point of view regenerative:2.
ensure its volume and survival;
3. give a regenerative start-up to all the retinal elements,
through the secretion of paracrine growth factors.
As it is well known, the dry AMD shows a damage starting
from foveal area, populated by cones, which typically has a
reduced cellularity.
Extrafoveal areas, mainly populated by rods, typically
appear better preserved.
Scotopic ERG is an outer retina function, so an increase of
it implies an improvement in the ability to respond to stimu-
lation by the photoreceptors.
LRRT (grafting of mature fat cells and ADSCs in SVF
enriched with PRP) seems to have a positive effect on the
increase in the various ERG values. This effect may be exer-
cised due to the paracrine secretion properties of these cells, we
hypothesize, including growth factors.
Consequently, retinal electrofunctional tests, that record
-field ERG responses, show different results after 30 days
the LRRT surgery technique. Unfortunately, in this pilot
y, it was not possible to show data of the multifocal ERG,
yright # 2014 Wolters Kluwer Health, Inc. All rights reserved.that records electrical responses from the different areas of the
retina, because some patients had poor central fixation lack.
Analogous difficulty was obtained for statistical analysis by
microperimetry Maia and standard perimetry Octopus.
However, the most significant increase is recorded by
scotopic ERG, whereas the less significant is the one recorded
by photopic-ERG. The position of the graft near the choroid
could allow at the product factors to flow into the choroidal
flow, to reach receptors of endothelial cells, RPEs, Mu¨ller cells,
photoreceptors, and potentially to interact with them. So, the
mechanism of this effect may be due to the growth factors’
action on trophic photoreceptors introduced at the level of the
retinal choriocapillaris through its contact with cell autologous
graft. The foveal damage, mainly in the dry AMD, and the
resulting reduced presence of cones at this level would explain
the less significant increase of photopic ERG. Conversely, the
best preservation of extrafoveal areas, and the consequent
increased presence of rods in those areas, would explain the
most significant increase of the scotopic ERG recorded
response. In fact, growth factors need still viable cells, which
possess the corresponding membrane receptors.
Following the complex growth factor receptor formation, a
limited number of second messengers are generated within the
cell target. These in turn control a series of biochemical path-
ways within the cell, by regulating the enzyme activity and
transcription factors, through a series of cascade of phosphoryl-
ation events.40–44 These signals, arrived in the nucleus of the
cell, determine changes in the response of genes, increasing
proteins, enzymes, and cytokine transcription that play their role
in cell trophic control.40–44
The main function of growth factors is the external control
of the cell cycle, by the cell quiescence abandonment (G0
phase) and the cell entry in the G1 phase (growth). However,
this is not their only function; they can regulate the entry into
mitosis, cell survival, migration, and cell differentiation.40,41
ere not statistically significant. Left Panel. BCVA for far distance in
cted visual acuity, logMAR¼ logarithm of the minimum angle ofand e1.The LRRT allows the grafting of 3 autologous components
ach of the grafted elements has its own specific assets inFat cells, contained in the pedicle placed in the
suprachoroidal space, produce basic fibroblast growth
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6 |factor (bFGF), epidermal growth factor (EGF), insulin-like
oli et algrowth factor-1 (IGF-1), interleukin (IL), transforming
growth factor-b (TGF-b), pigment-epithelium-derived
factor (PEDF), and adiponectin.14–17
The ADSCs produce bFGF, vascular endothelial growth
factor (VEGF), macrophage colony-stimulating factor
(M-CSF), granulocyte-macrophage colony-stimulating
factor (GM-CSF), placental growth factor (PlGF),
TGF-b, hepatocyte growth factor, IGF-1, IL, and angio-
genin.25–27,44
Platelets produce platelet-derived growth factor (PDGF),3.
IGF-1, TGF-b, VEGF, bFGF, EGF, platelet-derived
angiogenesis factor (PDAF), and thrombospondin
(TSP).23,24
Some factors, such as VEGF, bFGF, angiogenin, PDAF,
PlGF, PDGF, EGF, and TGF- b, promote endothelial regener-
ation and may contribute to the choriocapillaris reperfu-
sion.42,43,45 VEGF introduced with the PRP stimulates
ADSCs proliferation that in turn promote both the autologous
fat and adipocytes survival.38,39,42
Others, such as the TSP and the PEDF inhibit neovascular
processes;46–48 bFGF acts directly on the photoreceptor, bind-
ing to the surface receptors and promotes their survival.46–
48,10,49 The PEDF similarly to bFGF has neurotrophic activity in
respect of the photoreceptors.50
Some factors, however, as the EGF, act on Mu¨ller cells
inducing endogenous bFGF transcription and strengthen the
protective action of these cells toward the retina nerve cells.51–
53 EGF also stimulates the ADSCs to increase its secretory
activity.54
Furthermore, bFGF, IGF-1, PEDF, PDGF, TGF-b, and
VEGF are normally secreted by RPEs, which in the presence of
maculopathy to atrophic evolution are pathologically deficient
for the involution of RPEs/choriocapillaris system. Their para-
crine secretion by cell graft helps to promote the photoreceptor
and choriocapillaris survival.55–59
Moreover, M-CSF, GM-CSF, and IL have an anti-inflam-
matory component and a chemotactic one toward macrophages
that contribute to remove cell intraretinal debris and function
normally carried out by RPEs.60–63 Also from an experimental
point of view, increases in the number of macrophages have
been observed after intravitreal injection of bFGF.11,44
From the results of our study, with LRRT technique it
seems possible to achieve, directly and indirectly, an increase in
choroidal perfusion and a greater tropism of the photoreceptors
through bFGF–receptor interactions and stimulation mediated
byMu¨ller cells, RPEs, and retinal photoreceptors. Successively,
these events would allow a growth of the cellular activity to
facilitate appropriate potentials of action.
It is possible affirm that an improved cell trophism trans-
lates into an electrical activity increase of the cell, which can be
measured objectively through the classic electrofunctional test-
ing as evidenced in our results. In the near future, we will
continue the researches by the enrollment of the largest number
subjects with more visual acuity and central fixed, through the
statistical valuation of all the indispensable examinations to
confirm technique validity and study of biochemical effects.
CONCLUSION
From a clinical point of view, cell-mediated therapy based
he use of growth factors appears interesting because they
improve the electrical cell responses in the short term. The
www.md-journal.comERG could, therefore, be used to monitor in an objective
manner in humans, similar to the guinea pigs, the effect of
regenerative cellular-mediated therapies, including autologous
fat orbital joint to cells derived from ADSCs in adipose tissue
SVF and PRP (LRRT). It is possible to assume a greater effect
even at foveal level provided that it is applied early, such as to
allow a broader cytokine–receptor interaction, when most of
the photoreceptors are still present. Therefore, we have to take
into account that the cell-mediated administration of growth
factors can be realized by using a scleral surgery.
In summary, it seems essential in the future to investigate
the long-term effectiveness of this therapy, the cost-benefit ratio
of the intervention, the best time of intervention, and the real
security for the future visual acuity of our patients.
ACKNOWLEDGMENTS
We are grateful to Profs Pierpaolo D’Urso and Riccardo
Massari, Sapienza University of Rome, for their help in super-
vising and guiding in statistical analysis.
REFERENCES
1. Zhang K, Hopkins JJ, Heier JS, et al. Ciliary neurotrophic factor
delivered by encapsulated cell intraocular implants for treatment of
geographic atrophy in age-related macular degeneration. Proc Natl
Acad Sci U S A. 2011;108:6241–6245.
2. Okoye G, Zimmer J, Sung J, et al. Increased expression of brain-
derived neurotrophic factor preserves retinal function and slows cell
death from rhodopsin mutation or oxidative damage. J Neuroscience.
2003;23:4164–4172.
3. Chaum E. Retinal neuroprotection by growth factors: a mechanistic
perspective. J Cellular Biochem. 2003;88:57–75.
4. Thanos C, Emerich D. Delivery of neurotrophic factors and
therapeutic proteins for retinal diseases. Expert Opin Biol Ther.
2005;5:1443–1452.
5. Sakai T, Kuno N, Takamatsu F, et al. Prolonged protective effect of
basic fibroblast growth factor-impregnated nanoparticles in royal
college of surgeons rats. Invest Ophthalmol Vis Sci. 2007;48:3381–
3387.
6. Wen R, Song Y, Liu Y, et al. CNTF negatively regulates the
phototransduction machinery in rod photoreceptors: implication for
light-induced photostasis plasticity. Adv Exp Med Biol.
2008;613:407–413.
7. Vergara NM, Del Rio-Tsonis K. Retinal regeneration in the Xenopus
laevis tadpole: a new model system. Mol Vis. 2009;15:1000–1013.
8. Daftarian N, Kiani S, Zahabi A. Regenerative therapy for retinal
disorders. J Ophthalmic Vis Res. 2010;5:250–264.
9. Wen R, Tao W, Luo L, et al. Regeneration of cone outer segments
induced by CNTF. Adv Exp Med Biol. 2012;723:93–99.
10. LaVail MM, Faktorovich EG, Hepler JM, et al. Basic fibroblast
growth factor protects photoreceptors from light-induced degenera-
tion in albino rats. Ann N Y Acad Sci. 1991;638:341–347.
11. La Vail MM, Unok K, Yasumura D, et al. Multiple growth factors,
cytokines, and neurotrophins rescue photoreceptors from the dama-
ging effects of constant light. Proc Natl Acad Sci USA.
1992;89:11249–11253.
12. Sampat KM, Garg SJ. Complications of intravitreal injections. Curr
Opin Ophthalmol. 2010;21:178–183.
Medicine  Volume 93, Number 29, December 201413. Levine JP, Marcus I, Sorensen JA, et al. Macular hemorrhage in
neovascular age-related macular degeneration after stabilization with
antiangiogenic therapy. Retina. 2009;29:1074–1079.
Copyright # 2014 Wolters Kluwer Health, Inc. All rights reserved.
14. Wang P, Mariman E, Renes J, et al. The secretory function of
adipocytes in the physiology of white adipose tissue. J Cell Physiol.
2008;216:3–13.
15. Trayhurn P, Beattie JH. Physiological role of adipose tissue: white
adipose tissue as an endocrine and secretory organ. Proc Nutr Soc.
2001;60:329–339.
16. Scherer PE. Adipose tissue: from lipid storage compartment to
endocrine organ. Diabetes. 2006;55:1537–1545.
17. Tilg H, Moschen A. Adipocytokines: mediators linking adipose
tissue, inflammation and immunity. Nature Rev Immunol.
2006;6:772–783.
18. Filatov VP. Tissue therapy. Med Gen Fr. 1951;11:3–5.
19. Pelaez O. Retinitis pigmentosa. Cuban experience. Editorial Cienti-
fico Te´cnica. La Habana, 1997.
20. Meduri R, Scorolli L, Morara M, et al. Effect of basic fibroblast
growth factor on the retinal degeneration of B6(A)- Rperd12/J
(retinitis pigmentosa) mouse: a morphologic and ultrastructure study.
ARVO 2007 Annual Meeting, Fort Lauderdale, May 6–10, 2007.
21. Limoli PG, Carpi R, Tassi, et al. Adipocyties subscleral implant.
Growth factors may be considered a new therapy of atrophic retinal
pathology? Invest Ophthalmol Vis Sci. 2011;52:437ARVO Meeting.
22. Limoli PG, Carpi R, Tassi, et al. Prognostic standard in growth
factors therapy. Invest Ophthalmol Vis Sci. 2012;53:277ARVO Meet-
ing.
23. Tischler M. Platelet rich plasma: the use of autologous growth
factors to enhance bone and soft tissue grafts. N Y State Dent J.
2002;68:22.
24. Kevy SV, Jacobson MS, Blasetti L, et al. Preparation of growth
factor enriched autologous platelet gel. Transactions of the Society
for Biomaterials 27th Annual Meeting, St. Paul, Minnesota, USA.
April 24–29, 2001.
25. Nakagami H, Morishitah R, Maeda K, et al. Adipose tissue-derived
stromal cells as a novel option for regenerative cell therapy. J
Atheroscler Thromb. 2006;13:77–81.
26. Schaffler A, Buchler C. Concise review: adipose tissue-derived
stromal cells-basic and clinical implications for novel cell-based
therapies. Stem Cells. 2007;25:818–882.
27. Prunet-Marcassus B, Cousin B, Caton D, et al. From heterogeneity
to plasticity in adipose tissues: site-specific differences. Exp Cell
Res. 2006;312:727–736.
28. Mao H, James T Jr, Schwein A, et al. AAV delivery of wild-type
rhodopsin preserves retinal function in a mouse model of autosomal
dominant retinitis pigmentosa. Hum Gene Ther. 2011;22:567–575.
29. Gerth C. The role of the ERG in the diagnosis and treatment of age-
related macular degeneration. Doc Ophthalmol. 2009;118:63–68.
30. Marmor MF, Fulton AB, Holder GE, et al. Standard for clinical
electroretinography (2008 update). Doc Ophthalmol. 2009;118:69–
77.
31. Skaat A, Solomon A, Moroz I, et al. Increased electroretinogram a-
wave amplitude after intravitreal bevacizumab injection for neovas-
cular age-related macular degeneration. Acta Ophthalmol.
2011;89:e269–e273.
32. Mackay AM, Brown MC, Hagan RP, et al. Deficits in the
electroretinogram in neovascular age-related macular degeneration
and changes during photodynamic therapy. Doc Ophthalmol.
2007;115:69–76.
33. Maturi RK, Bleau LA, Wilson DL. Electrophysiologic findings after
intravitreal bevacizumab (Avastin) treatment. Retina. 2006;26:270–
Medicine  Volume 93, Number 29, December 2014274.
34. Nebbioso M, Livani ML, Steigerwalt RD, et al. Retina in rheumatic
diseases: standard full field and multifocal electroretinography in
Copyright # 2014 Wolters Kluwer Health, Inc. All rights reserved.hydroxychloroquine retinal dysfunction. Clin Exp Optom.
2010;94:276–283.
35. Werko L. Ethics committees bear a responsibility for patient
information. Informed consent implies that the patient understands
what he has consented to. Lakartidningen. 2002;99:1552–1555.
36. Coleman WP, Glogau RG, Klein JA, et al. Guidelines of care for
liposuction. J Am Acad Dermatol. 2001;45:438–447.
37. Lawrence N, Coleman WP. Liposuction. J Am Acad Dermatol.
2002;47:105–108.
38. Luo S, Hao L, Li X, et al. Adipose tissue-derived stem cells treated
with estradiol enhance survival of autologous fat transplants. Tohoku
J Exp Med. 2013;231:101–110.
39. Chen G, Shi X, Sun C, et al. VEGF-mediated proliferation of human
adipose tissue-derived stem cells. PLoS One. 2013;8:e73673.
40. Finklestein SP, Plomaritoglou A. Growth factors. In Miller LP,
Hayes RL, eds. Newcomb JK, co-editor. Head Trauma: Basic,
Preclinical, and Clinical Directions. New York: Wiley; 2001:165–
187.
41. Limoli P. The retinal cell-neuroregeneration. Principles, applications
and perspectives. The growth factors [Italian]. FGE Reg. San
Giovanni 40, Canelli (AT). Ed. 2014, 159–206.
42. Bagchi M, Kim LA, Boucher J, et al. Vascular endothelial growth
factor is important for brown adipose tissue development and
maintenance. FASEB J. 2013;27:3257–3271.
43. Khurana R, Moons L, Shafi S, et al. Placental growth factor
promotes atherosclerotic intimal thickening and macrophage accumu-
lation. Circulation. 2005;111:2828–2836.
44. Sansone L, Reali V, Pellegrini L, et al. SIRT1 inhibition confers
neuroresistance in vitro through IGF-1 pathway activation. J Cell
Physiol. 2013;228:1754–1761.
45. Schreiber AB, Winkler ME, Derynck R. Transforming growth
factor-alpha: a more potent angiogenic mediator than epidermal
growth factor. Science. 1986;232:1250–1253.
46. Sheibani N, Sorenson CM, Cornelius LA, et al. Thrombospondin-1,
a natural inhibitor of angiogenesis, is present in vitreous and aqueous
humor and is modulated by hyperglycemia. Biochem Biophys Res
Commun. 2000;267:257–261.
47. Carron JA, Hiscott P, Hagan S, et al. Cultured human retinal
pigment epithelial cells differentially express thrombospondin-1, -2,
-3, and -4. Int J Biochem Cell Biol. 2000;32:1137–1142.
48. Dawson DW, Volpert OV, Gillis P, et al. Pigment epithelium-
derived factor: a potent inhibitor of angiogenesis. Science.
1999;285:245–248.
49. Sakaguchi DS, Janick LM, Reh TA. Basic fibroblast growth factor
(FGF-2) induced transdifferentiation of retinal pigment epithelium:
generation of retinal neurons and glia. Dev Dyn. 1997;209:387–398.
50. Kim SY, Mocanu C, McLeod DS, et al. Expression of pigment
epithelium-derived factor (PEDF) and vascular endothelial growth
factor (VEGF) in sickle cell retina and choroid. Exp Eye Res.
2003;77:433–445.
51. Ueki Y, Reh TA. EGF stimulates Mu¨ller glial proliferation via a
BMP-dependent mechanism. Glia. 2013;61:778–789.
52. Hauck SM, Kinkl N, Deeg CA, et al. GDNF family ligands trigger
paracrine neuroprotective signalling in retinal glial cells. Cell Biol.
2006;26:2746–2757.
53. Zack DJ. Neurotrophic rescue of photoreceptors: are Mu¨ller cells the
Electroretinogram After Autograft in AMDmediators of survival? Neuron. 2000;26:285–286.
54. Li Q, Li PH, Hou DJ, et al. EGF enhances ADSCs secretion via
ERK and JNK pathways. Cell Biochem Biophys. 2014;69:189–196.
www.md-journal.com | 7
55. Kozlowski MR. RPE cell senescence: a key contributor to age-
related macular degeneration. Elsevier Med Hypotheses.
2012;78:505–510.
56. Bhutto I, Lutty G. Understanding age-related macular degeneration
(AMD): relationships between the photoreceptor/retinal pigment
epithelium/Bruch’s membrane/choriocapillaris complex. Mol Aspects
Med. 2012;33:295–317.
57. Campochiaro PA, Hackett SF, Vinores SA, et al. Platelet-derived
growth factor is an autocrine growth stimulator in retinal pigmented
epithelial cells. J Cell Sci. 1994;107:2459–2469.
Limoli et al58. Slomiany MG, Rosenzweig SA. Autocrine effects of IGF-I-induced
VEGF and IGFBP-3 secretion in retinal pigment epithelial cell line
ARPE-19. Am J Physiol Cell Physiol. 2004;287:C746–753.
8 | www.md-journal.com59. Tanihara H, Yoshida M, Matsumoto M, et al. Identification of
transforming growth factor-beta expressed in cultured human retinal
pigment epithelial cells. Invest Ophthalmol Vis Sci. 1993;34:413–
419.
60. Nemunaitis J. Macrophage function activating cytokines: potential
clinical application. Crit Rev Oncol Hematol. 1993;14:153–171.
61. Schneider A, Kru¨ger C, Steigleder T, et al. The hematopoietic factor
G-CSF is a neuronal ligand that counteracts programmed cell death
and drives neurogenesis. J Clin Invest. 2005;115:2083–2098.
62. Dinarello CA. The IL-1 family and inflammatory diseases. Clin Exp
Rheumatol. 2002;20 (S27):S1–S13.
Medicine  Volume 93, Number 29, December 201463. Yin Y, Henzl MT, Lorber B, et al. Oncomodulin is a macrophage-
derived signal for axon regeneration in retinal ganglion cells. Nat
Neurosci. 2006;9:843–852.
Copyright # 2014 Wolters Kluwer Health, Inc. All rights reserved.
